Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of A
about
HER2 heterogeneity in gastric/gastroesophageal cancers: From benchside to practiceHER2 testing in gastric cancer: An updateHER2 expression beyond breast cancer: therapeutic implications for gynecologic malignanciesChromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomasHER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancerDevelopment of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridHER2 and GATA4 are new prognostic factors for early-stage ovarian granulosa cell tumor-a long-term follow-up study.Image analysis as an adjunct to manual HER-2 immunohistochemical review: a diagnostic tool to standardize interpretationOut of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinomaConfirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridizationDetermination of HER-2 status on FNAC material from breast carcinomas using in situ hybridization with dual chromogen visualization with silver enhancement (dual SISH).Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.Testing for HER2 in Breast Cancer: A Continuing Evolution.SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches.High-density SNP arrays improve detection of HER2 amplification and polyploidy in breast tumorsEGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer.Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method.Multiplication of Chromosome 17 Centromere Is Associated with Prognosis in Patients with Invasive Breast Cancers Exhibiting Normal HER2 and TOP2A Status.Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer.Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections.HER2 Status by Standardized Immunohistochemistry and Silver-Enhanced In Situ Hybridization in Korean Breast CancerDelineation of HER2 gene status in breast carcinoma by silver in situ hybridization is reproducible among laboratories and pathologists.EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy.HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.Update on HER2 testing for breast and upper gastrointestinal tract cancers.Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.Diagnostic applications of fluorescence in situ hybridization.Evaluation of HER2 in breast cancer: reality and expectations.HER2 assessment by silver in situ hybridization: where are we now?Effect of menstrual cycle and menopausal status on apparent diffusion coefficient values and detectability of invasive ductal carcinoma on diffusion-weighted MRI.Instant-quality fluorescence in-situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study.Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens.The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system.Validity of immunohistochemistry method in predicting HER-2 gene status and association of clinicopathological variables with it in invasive breast cancer patients.The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.Silver-Enhanced In Situ Hybridization as an Alternative to Fluorescence In Situ Hybridization for Assaying HER2 Amplification in Clinical Breast Cancer.HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH)Problems In Determining Her2 Status In Breast Carcinoma.HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing.
P2860
Q26741253-97AEE176-28D9-48E1-B27B-48631F05EDD9Q26746253-15BECAA7-95AE-438B-9298-5BB1730B9A21Q26822730-60BD06DF-64D2-4950-89D0-281EE0AF89CCQ26865068-6D8C113F-3C5E-4025-A832-F1D013A998C3Q30837184-CAF41F9F-A22A-40BF-B1B5-DB24EA115DB9Q33378811-9DC6EF50-DD6C-419B-A0ED-EDD57B0682D6Q33913521-B2F192E6-C45C-4E21-8005-7C382E31AA01Q34044859-2966C1E4-F927-4BC6-8C36-D6809DBFC4AAQ34064466-940A26ED-908B-4015-A886-47A4AD1E9DEFQ34071408-D2BC08E7-C126-4969-A637-E614C47AF168Q34204064-4EE36848-4915-49BD-B022-479D5232F68DQ34248282-3942A4F4-302A-46EE-9805-535BABD93535Q34424285-E4FFA2F0-DF17-437D-B279-57A3C82C4D2FQ34855870-AF985E04-E3D0-47BE-9A84-7F14CA633AD1Q35034555-BCB2B6B7-6C82-4C19-A09D-709738C0D6B6Q35078859-480D79A5-C033-42F0-950D-B98BCEEC9F6DQ35125640-C2FF49FA-FB91-4459-97E1-07C452292FA1Q35195417-991F3184-CE03-487E-8871-DDE4F294EEEEQ35866923-EABA63B9-DA2F-4FFF-A162-8A73C9854611Q35983145-DD6B14D8-CC5B-4EC8-A915-5B2F136C9777Q36186764-57024EA8-0F39-4BAB-9598-BD1F75B11156Q36525801-B304F584-3114-4802-8E61-75F6AF6B35DBQ36944264-2F080643-E92D-4E15-AA3F-67F53CA22E53Q37206247-44232AC5-3824-4B09-8B59-7912638DBA60Q37241515-615D91B8-FB19-47B0-9A8A-2361061B1A3AQ37886993-3F6C64E5-14A5-4211-B0B3-D79F650DD711Q37889274-9F319120-7BD9-46F8-8B9E-37FCA88673B8Q38088857-A55766FD-069B-4DF2-B64F-29E5633CD041Q38089837-1D3E746A-7C23-4E30-ABFE-3D15B7C0089CQ38314355-1F045AE3-7F0E-4AD3-B74E-69B216F77C71Q38338845-18805886-5C80-45BB-8EBD-1CE3C8169AA9Q38394606-41A3EE82-E1D0-46EA-9844-1BF5AF19A732Q38612634-489AAC5A-D068-4AC1-AB65-8C3A6F03BD0FQ38907580-F45A91EA-1A5C-4EF9-A61F-C5008A75EB64Q39022194-443C8E29-00D4-49A4-8F91-A85C10711716Q39201898-B6B286B2-1B38-48AB-AC0C-3AFDCDAFB450Q40748887-9921AE80-9B59-4686-B585-356990ADBE79Q41880900-8F6A93F9-9B0A-4E9F-A19B-AFCD483159ECQ42316292-70A0A120-E3A7-4D96-82A5-ACF26D98CD07Q42431264-D9AB19A5-BD79-4361-AD5B-B4EC126F5678
P2860
Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of A
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Comparison of automated silver ...... Oncology and the College of A
@en
Comparison of automated silver enhanced in situ hybridisation
@nl
type
label
Comparison of automated silver ...... Oncology and the College of A
@en
Comparison of automated silver enhanced in situ hybridisation
@nl
prefLabel
Comparison of automated silver ...... Oncology and the College of A
@en
Comparison of automated silver enhanced in situ hybridisation
@nl
P2093
P1433
P1476
Comparison of automated silver ...... llege of American Pathologists
@en
P2093
G Kristiansen
P2888
P356
10.1007/S00428-007-0424-5
P50
P577
2007-06-12T00:00:00Z